Shopping Cart 0
Cart Subtotal
USD 0

Sorrento Therapeutics Inc (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Sorrento Therapeutics Inc (STI), formerly QuikByte Software Inc, is a cancer therapeutic service provider. The company offers CD38 CAR-T, lidocaine topical system, resiniferatoxin. Its product pipeline includes CD38 CAR-T, CEA CAR-T, CD38 ADC and seprehvir. STI provides treatment for multiple myeloma, metastatic liver tumors and solid tumors. The company offers therapies for immune oncology, pain management and ark animal health. It offers G-MAB technology, CAR-T, ADCs, iTAbs, oncolytic virus. STI offers research and development and clinical trials. The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. STI is headquartered in San Diego, California, the US.

Sorrento Therapeutics Inc (SRNE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Sorrento Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Sorrento Therapeutics Acquires Sofusa Platform from Kimberly-Clark 17

Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 18

Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 19

Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 20

Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins 21

Venture Financing 22

Celularity Raises USD250 Million in Venture Financing 22

Celularity Raises Funds through Series A Financing 24

Scilex Pharma Raises USD0.5 Million in Financing 25

Globavir Biosciences Secures USD4 Million in Venture Funding 26

Scilex Pharma Raises USD 5 Million In Venture Financing 27

Partnerships 28

Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies 28

Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 29

Sorrento Therapeutics to Form Joint Venture with CHA Biotech 31

TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 32

Sorrento Therapeutics Forms Joint Venture with Yuhan 33

Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 34

Sorrento Therapeutics forms Joint Venture with City of Hope 35

Sorrento Therapeutics and NantBioscience Form Joint Venture 36

Advaxis Enters into Research Agreement with Sorrento Therapeutics 37

Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 38

NantWorks to Form Joint Venture with Sorrento Therapeutics 39

Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 40

Licensing Agreements 41

Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 41

Sorrento Therapeutics Enters into Licensing Agreement with City of Hope 42

Sorrento Therapeutics Enters into Licensing Agreement with Mabtech 43

Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences 44

NantWorks Enters into Licensing Agreement with Sorrento Therapeutics 45

NantCell Enters into Licensing Agreement with Sorrento Therapeutics 46

Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 47

Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 48

Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute 49

Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones 50

Equity Offering 51

Sorrento Therapeutics Files Registration Statement to Raise up to USD269 Million in Public Offering of Shares 51

Sorrento Therapeutics to Raise up to USD100 Million in Public Offering of Shares 52

Sorrento Therapeutics Plans to Raise Funds through Private Placement of Shares 53

Sorrento Therapeutics to Raise Funds through Public Offering of Shares 54

Sorrento Therapeutics Raises USD47.3 Million in Public Offering of Shares 55

Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants 57

Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants 58

Sorrento Therapeutics Raises USD28.8 million in Public Offering of Shares 60

Scilex Pharma Raises USD5 Million in Private Placement Of Shares And Warrants 62

Sorrento Therapeutics Completes Public Offering Of Shares For USD 34.6 Million 63

Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To USD 100 Million 65

Debt Offering 66

Scilex Pharma Raises USD140 Million in Private Placement of Notes Due 2026 66

Sorrento Therapeutics to Raise USD120.5 Million in Private Placement of 5% Notes 67

Sorrento Therapeutics Raises USD50 Million in Private Placement of 5% Notes and Warrants 68

Sorrento Therapeutics Raises USD1.9 Million in Public Offering of Notes 69

Asset Transactions 70

Celularity Acquires Assets from TNK Therapeutics 70

Acquisition 71

TNK Therapeutics Acquires Virttu Biologics 71

Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 72

TNK Therapeutics Acquires Two Biotechnology Companies 73

NantPharma Acquires IgDraSol from Sorrento Therapeutics 74

Itochu Chemical Frontier Invests in Scilex Pharma 75

NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million 76

Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To USD 12 Million 77

Sorrento Acquires Sherrington, Chronic Pain Therapies Provider 78

Sorrento Therapeutics Completes Acquisition Of IgDraSol For USD 28.2 Million 79

Sorrento Therapeutics Inc-Key Competitors 81

Sorrento Therapeutics Inc-Key Employees 82

Sorrento Therapeutics Inc-Locations And Subsidiaries 83

Head Office 83

Other Locations & Subsidiaries 83

Joint Venture 84

Recent Developments 85

Strategy And Business Planning 85

May 04, 2017: Sorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business 85

Corporate Communications 86

Mar 19, 2018: Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018 86

Oct 02, 2017: Sorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors 87

Legal and Regulatory 88

Jun 14, 2017: Sorrento Therapeutics Announces Dismissal Of Lawsuits 88

Product News 89

Aug 21, 2017: Celularity Accelerates Breakthrough Placental Discovery & Therapeutic Platform 89

06/14/2017: Sorrento Therapeutics' Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido 90

02/28/2018: Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for PHN Pain 91

01/09/2017: Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido 93

Product Approvals 94

Nov 14, 2017: Scilex Pharmaceuticals, Sorrento Therapeutics Subsidiary, Files Marketing Authorization Application In The European Union For ZTlido 94

Aug 29, 2017: Sorrento Therapeutics Submits NDA For ZTlido Next-Generation Lidocaine Patch 95

Jun 29, 2017: Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain 96

Clinical Trials 97

Sep 07, 2018: Scilex Presents ZTlido Data on Superior Adhesion over Lidocaine Patch Formulation 97

Feb 05, 2018: Sorrento's and Yuhan's Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1 Monoclonal Antibody in South Korea 99

Jan 29, 2018: China Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrento's Anti-PD-L1 Monoclonal Antibody 100

Other Significant Developments 101

Mar 28, 2018: Sorrento Therapeutics Chairman/CEO update to stockholders 101

Feb 05, 2018: Sorrento Therapeutics Chairman/CEO letter to stockholders 102

Appendix 104

Methodology 104

About GlobalData 104

Contact Us 104

Disclaimer 104


List Of Figure

List of Figures

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Sorrento Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Sorrento Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Sorrento Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Sorrento Therapeutics Acquires Sofusa Platform from Kimberly-Clark 17

Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 18

Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 19

Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 20

Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins 21

Celularity Raises USD250 Million in Venture Financing 22

Celularity Raises Funds through Series A Financing 24

Scilex Pharma Raises USD0.5 Million in Financing 25

Globavir Biosciences Secures USD4 Million in Venture Funding 26

Scilex Pharma Raises USD 5 Million In Venture Financing 27

Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies 28

Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 29

Sorrento Therapeutics to Form Joint Venture with CHA Biotech 31

TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 32

Sorrento Therapeutics Forms Joint Venture with Yuhan 33

Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 34

Sorrento Therapeutics forms Joint Venture with City of Hope 35

Sorrento Therapeutics and NantBioscience Form Joint Venture 36

Advaxis Enters into Research Agreement with Sorrento Therapeutics 37

Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 38

NantWorks to Form Joint Venture with Sorrento Therapeutics 39

Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 40

Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 41

Sorrento Therapeutics Enters into Licensing Agreement with City of Hope 42

Sorrento Therapeutics Enters into Licensing Agreement with Mabtech 43

Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences 44

NantWorks Enters into Licensing Agreement with Sorrento Therapeutics 45

NantCell Enters into Licensing Agreement with Sorrento Therapeutics 46

Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 47

Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 48

Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute 49

Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones 50

Sorrento Therapeutics Files Registration Statement to Raise up to USD269 Million in Public Offering of Shares 51

Sorrento Therapeutics to Raise up to USD100 Million in Public Offering of Shares 52

Sorrento Therapeutics Plans to Raise Funds through Private Placement of Shares 53

Sorrento Therapeutics to Raise Funds through Public Offering of Shares 54

Sorrento Therapeutics Raises USD47.3 Million in Public Offering of Shares 55

Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants 57

Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants 58

Sorrento Therapeutics Raises USD28.8 million in Public Offering of Shares 60

Scilex Pharma Raises USD5 Million in Private Placement Of Shares And Warrants 62

Sorrento Therapeutics Completes Public Offering Of Shares For USD 34.6 Million 63

Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To USD 100 Million 65

Scilex Pharma Raises USD140 Million in Private Placement of Notes Due 2026 66

Sorrento Therapeutics to Raise USD120.5 Million in Private Placement of 5% Notes 67

Sorrento Therapeutics Raises USD50 Million in Private Placement of 5% Notes and Warrants 68

Sorrento Therapeutics Raises USD1.9 Million in Public Offering of Notes 69

Celularity Acquires Assets from TNK Therapeutics 70

TNK Therapeutics Acquires Virttu Biologics 71

Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 72

TNK Therapeutics Acquires Two Biotechnology Companies 73

NantPharma Acquires IgDraSol from Sorrento Therapeutics 74

Itochu Chemical Frontier Invests in Scilex Pharma 75

NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million 76

Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To USD 12 Million 77

Sorrento Acquires Sherrington, Chronic Pain Therapies Provider 78

Sorrento Therapeutics Completes Acquisition Of IgDraSol For USD 28.2 Million 79

Sorrento Therapeutics Inc, Key Competitors 81

Sorrento Therapeutics Inc, Key Employees 82

Sorrento Therapeutics Inc, Subsidiaries 83

Sorrento Therapeutics Inc, Joint Venture 84

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Sorrento Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.